TherapeuticsMD (TXMD) Reports Q1 Loss of $0.06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
TherapeuticsMD Announces First Quarter 2025 Financial Results
May 13, 2025 4:05 PM EDTBOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (TherapeuticsMD or the Company) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025.
First Quarter 2025 Financial Results
Net Loss from Continuing Operations
Net loss from continuing operations was $(636) thousand, or $(0.06) per basic and diluted common share, a decrease of $99 thousand, compared to net loss from continuing operations of $(809) thousand, or $(0.07) per basic and diluted common share, for the first quarter of 2024.License Revenues from Continuing... More
